Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

NewsGuard 100/100 Score
Nov 19 2010

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

The poster's abstract details are as follows:

The abstract is available online at http://ash.confex.com/ash/2010/webprogram/start.html.

Source: Cyclacel Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

The New Picus® 2 sets a new standard for connected electronic pipettes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood